117 related articles for article (PubMed ID: 15236794)
21. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
Tariot PN
J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
[TBL] [Abstract][Full Text] [Related]
22. A review of antioxidants and Alzheimer's disease.
Frank B; Gupta S
Ann Clin Psychiatry; 2005; 17(4):269-86. PubMed ID: 16402761
[TBL] [Abstract][Full Text] [Related]
23. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.
Eskander MF; Nagykery NG; Leung EY; Khelghati B; Geula C
Brain Res; 2005 Oct; 1060(1-2):144-52. PubMed ID: 16212945
[TBL] [Abstract][Full Text] [Related]
24. Treatment possibilities of Alzheimer's disease.
Miklya I; Gaszner P
Neuropsychopharmacol Hung; 2004 Dec; 6(4):200-9. PubMed ID: 15825676
[TBL] [Abstract][Full Text] [Related]
25. Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease.
Gasparini L; Ongini E; Wilcock D; Morgan D
Brain Res Brain Res Rev; 2005 Apr; 48(2):400-8. PubMed ID: 15850679
[TBL] [Abstract][Full Text] [Related]
26. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain.
Enz A; Gentsch C
Neuropharmacology; 2004 Sep; 47(3):408-13. PubMed ID: 15275830
[TBL] [Abstract][Full Text] [Related]
27. Active site directed docking studies: synthesis and pharmacological evaluation of cis-2,6-dimethyl piperidine sulfonamides as inhibitors of acetylcholinesterase.
Girisha HR; Narendra Sharath Chandra JN; Boppana S; Malviya M; Sadashiva CT; Rangappa KS
Eur J Med Chem; 2009 Oct; 44(10):4057-62. PubMed ID: 19493592
[TBL] [Abstract][Full Text] [Related]
28. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
Hampel H; Shen Y
Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117
[TBL] [Abstract][Full Text] [Related]
29. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
Darvesh S; Arora RC; Martin E; Magee D; Hopkins DA; Armour JA
Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845
[TBL] [Abstract][Full Text] [Related]
30. Aging-resistant organophosphate bioscavenger based on polyethylene glycol-conjugated F338A human acetylcholinesterase.
Mazor O; Cohen O; Kronman C; Raveh L; Stein D; Ordentlich A; Shafferman A
Mol Pharmacol; 2008 Sep; 74(3):755-63. PubMed ID: 18523134
[TBL] [Abstract][Full Text] [Related]
31. The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis.
Sugimoto H
Chem Biol Interact; 2008 Sep; 175(1-3):204-8. PubMed ID: 18577377
[TBL] [Abstract][Full Text] [Related]
32. Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 1: micronutrients.
Bourre JM
J Nutr Health Aging; 2006; 10(5):377-85. PubMed ID: 17066209
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomics in Alzheimer's disease.
Cacabelos R
Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236
[TBL] [Abstract][Full Text] [Related]
34. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301.
Hirvonen J; Kailajärvi M; Haltia T; Koskimies S; Någren K; Virsu P; Oikonen V; Sipilä H; Ruokoniemi P; Virtanen K; Scheinin M; Rinne JO
Clin Pharmacol Ther; 2009 May; 85(5):506-12. PubMed ID: 19129751
[TBL] [Abstract][Full Text] [Related]
35. [New therapeutic options in Alzheimer's disease].
García-Ruiz Espiga PJ; Echeverría A; García-Torres A; Contreras A
Rev Neurol; 2006 Apr 16-30; 42(8):478-81. PubMed ID: 16625510
[TBL] [Abstract][Full Text] [Related]
36. Vitamin E in neurodegenerative disorders: Alzheimer's disease.
Kontush K; Schekatolina S
Ann N Y Acad Sci; 2004 Dec; 1031():249-62. PubMed ID: 15753151
[TBL] [Abstract][Full Text] [Related]
37. Oxidative stress hypothesis in Alzheimer's disease: a reappraisal.
Praticò D
Trends Pharmacol Sci; 2008 Dec; 29(12):609-15. PubMed ID: 18838179
[TBL] [Abstract][Full Text] [Related]
38. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease.
Bohnen NI; Kaufer DI; Hendrickson R; Ivanco LS; Lopresti B; Davis JG; Constantine G; Mathis CA; Moore RY; DeKosky ST
Neurosci Lett; 2005 May 20-27; 380(1-2):127-32. PubMed ID: 15854764
[TBL] [Abstract][Full Text] [Related]
39. Imaging treatment effects in Alzheimer's disease.
Venneri A
Magn Reson Imaging; 2007 Jul; 25(6):953-68. PubMed ID: 17446028
[TBL] [Abstract][Full Text] [Related]
40. Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing!
Tabet N
Age Ageing; 2006 Jul; 35(4):336-8. PubMed ID: 16788077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
